Dept Of Defense- Defense Health Agency ( Dha)- Defense Health Agency
Radiopharmaceuticals
SUPPLY of LUTATHERA ( lutetium Lu 177 dotatate) and PLUVICTO ( lutetium Lu 177 vipivotide tetraxetan) - Clinical Utility: It is used for targeted radioligand therapy for specific types of prostate cancer within the Nuclear Medicine Division of the Department of Radiology at WRNMMC. Novartis Pharmaceuticals Corporation is the sole source for Pluvicto
Supply of Lutathera ( lutetium Lu 177 dotatate) and Pluvicto ( lutetium Lu 177 vipivotide tetraxetan) for targeted radioligand therapy Lutathera ( lutetium Lu 177 dotatate), Pluvicto ( lutetium Lu 177 vipivotide tetraxetan)